Anitha Roy

Anitha Roy

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RVRavichandran Veerasamy
Ravichandran Veerasamy
ARAnitha Roy
Anitha Roy
RKRohini Karunakaran
Rohini Karunakaran
HRHarish Rajak
Harish Rajak
A significant number of the anti-inflammatory drugs currently in use are becoming obsolete. These are exceptionally hazardous for long-term use because of their possible unfavourable impacts. Subsequently, in the ebb-and-flow decade, analysts and researchers are engaged in developing new anti-inflammatory drugs, and many such agents are in the later phases of clinical trials. Molecules with heterocyclic nuclei are similar to various natural antecedents, thus acquiring immense consideration from scientific experts and researchers. The arguably most adaptable heterocyclic cores are benzimidazoles containing nitrogen in a bicyclic scaffold. Numerous benzimidazole drugs are broadly used in the treatment of numerous diseases, showing promising therapeutic potential. Benzimidazole derivatives exert anti-inflammatory effects mainly by interacting with transient receptor potential vanilloid-1, cannabinoid receptors, bradykinin receptors, specific cytokines, 5-lipoxygenase activating protein and cyclooxygenase. Literature on structure–activity relationship (SAR) and investigations of benzimidazoles highlight that the substituent’s tendency and position on the benzimidazole ring significantly contribute to the anti-inflammatory activity. Reported SAR analyses indicate that substitution at the N1, C2, C5 and C6 positions of the benzimidazole scaffold greatly influence the anti-inflammatory activity. For example, benzimidazole substituted with anacardic acid on C2 inhibits COX-2, and 5-carboxamide or sulfamoyl or sulfonyl benzimidazole antagonises the cannabinoid receptor, whereas the C2 diarylamine and C3 carboxamide substitution of the benzimidazole scaffold result in antagonism of the bradykinin receptor. In this review, we examine the insights regarding the SARs of anti-inflammatory benzimidazole compounds, which will be helpful for researchers in designing and developing potential anti-inflammatory drugs to target inflammation-promoting enzymes.

23 November 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Amalan VenkatesanAmalan Venkatesan
Amalan Venkatesan
ARAnitha Roy
Anitha Roy
SKSRINIVASAN KULANDAIVEL
SRINIVASAN KULANDAIVEL
Vijayakumar NatesanVijayakumar Natesan
Vijayakumar Natesan
SKSung-Jin Kim
Sung-Jin Kim
Diabetic nephropathy (DN) has become a leading cause of end-stage renal failure worldwide. The goal of the current study was to examine the protective effects of chitosan-loaded p-Coumaric acid nanoparticles (PCNPs) in nephrotoxicity induced by streptozotocin (STZ). Because of the antidiabetic, anti-inflammatory, and antioxidant properties of PCNPs, the development of DN may be considerably decreased. In this study, the rats received a single intraperitoneal injection (i.p.) of STZ (45 mg/kg) to induce DN. PCNPs were given orally 80 mg/kg b.w to the rats for a duration of four weeks. Body weight, kidney weight, blood glucose, and insulin levels were measured at the end of the experiment. Serum and urine parameters were also examined, along with the histological, immunobiological, and tumor necrosis factor (TNF) and interleukin-6 (IL-6) expression of the nephrotic rats. To comprehend the impact of PCNPs, the expression patterns of the kidney injury molecule (KIM-1) and glucose transporter-2 (GLUT-2) were evaluated. Administration of PCNPs significantly increased body weight, decreased kidney weight and also ameliorated blood glucose levels in the nephropathic rats. The administration of PCNPs also reverted the levels of urea, serum creatinine, urinary NAG, β-glucuronidase and albumin to near-normal levels. The administration of PCNPs also caused the levels of serum and urine parameters to return to near-normal levels. Additionally, the PCNP-treated rats had markedly reduced TNF-α, IL-6, and KIM-1 expressions as well as enhanced GLUT-2 mRNA expression. Our findings clearly showed that PCNP administration prevents the onset of DN in rats by lowering hyperglycemia, decreasing inflammation, and improving the expression of GLUT-2 mRNA in nephropathic rats.

5 March 2017 in Pharmacognosy Journal
Verified
Journal Article
Open access
SAShenai Ashwini
Shenai Ashwini
DEDevaraj Ezhilarasan
Devaraj Ezhilarasan
ARAnitha Roy
Anitha Roy

1 January 2017 in Pharmacognosy Magazine
Verified
Journal Article
Open access
PDF file
ARAnitha Roy
Anitha Roy
SAShenai Ashwini
Shenai Ashwini
Background: An increase in prevalence of diabetes mellitus necessitates the need to develop new drugs for its effective management. Plants and their bioactive compounds are found to be an alternative therapeutic approach. Caralluma fimbriata, used in this study, is well known for its various biological effects. Objective: The present study was designed to investigate the antihyperglycemic effect of the ethanolic leaf extract of C. fimbriata. Materials and Methods: Different concentrations (1–1000 μ g/mL) of the ethanolic leaf extract of C. fimbriata were subjected to alpha-amylase and alpha-glucosidase inhibitory assay with acarbose as control. Cytotoxicity was assessed by 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Glucose uptake assay was performed on L6 myotubes using the extract in 1 μ g–100 μ g/mL, using metformin and insulin as control. Results: The C. fimbriata extract showed potent inhibitory activity on enzymes of glucose metabolism in a dose-dependent manner. The maximum alpha-amylase inhibitory effect was 77.37% ± 3.23% at 1000 μ g/mL with an IC50value of 41.75 μ g/mL and alpha-glucosidase inhibitory effect was 83.05% ± 1.69% at 1000 μ g/mL with an IC50value of 66.71 μ g/mL. The maximum glucose uptake was found to be 66.32% ± 0.29% for the Caralluma extract at 100 μ g/mL and that of metformin (10 μ g/mL) was 74.44% ± 1.72% and insulin (10 μ M) 85.55% ± 1.14%. The extract was found to be safe as the IC50of extract and metformin was found to be ≥1000 μ g/mL and ≥1000 μ M, respectively, in the cell line tested. Conclusion: The study concludes that C. fimbriata has promising antihyperglycemic activity. Abbreviations used: GLUT: Glucose transporter; MTT: 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.

27 November 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
SJSelvaraj Jayaraman
Selvaraj Jayaraman
ARAnitha Roy
Anitha Roy
DVDr. Srinivasan V
Dr. Srinivasan V
RSRamya sekar
Ramya sekar
VVVishnu Priya Veeraraghavan
Vishnu Priya Veeraraghavan
RMReji Manjunathan
Reji Manjunathan
Diabetes is one of the most significant health issues across the world. People identified with diabetes are more vulnerable to various infections and are at a greater risk of developing cardiovascular diseases. The plant-based food we consume often contains many sterol-based bioactive compounds. It is well documented that these compounds could effectively manage the processes of insulin metabolism and cholesterol regulation. Insulin resistance followed by hyperglycemia often results in oxidative stress level enhancement and increased reactive oxygen species production. At the molecular level, these changes induce apoptosis in pancreatic cells and hence lead to insulin insufficiency. Studies have proved that plant sterols can lower inflammatory and oxidative stress damage connected with DNA repair mechanisms. The effective forms of phyto compounds are polyphenols, terpenoids, and thiols abundant in vegetables, fruits, nuts, and seeds. The available conventional drug-based therapies for the prevention and management of diabetes are time-consuming, costly, and with life-threatening side effects. Thereby, the therapeutic management of diabetes with plant sterols available in our daily diet is highly welcome as there are no side effects. This review intends to offer an overview of the present scenario of the anti-diabetic compounds from food ingredients towards the therapeutic beneficial against diabetes.

1 January 2019 in Journal of Pharmacy and Bioallied Sciences
Verified
Journal Article
Open access
ARAnitha Roy
Anitha Roy
NANilamaideenNoorul Aneesa
NilamaideenNoorul Aneesa
SVSheeja Saji Varghese
Sheeja Saji Varghese
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society